StageZero Life Sciences (OTCMKTS:GNWSD) and Intellia Therapeutics (NASDAQ:NTLA) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.
Risk & Volatility
StageZero Life Sciences has a beta of 2.97, suggesting that its share price is 197% more volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 2.02, suggesting that its share price is 102% more volatile than the S&P 500.
This table compares StageZero Life Sciences and Intellia Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|StageZero Life Sciences||$140,000.00||204.15||-$3.48 million||N/A||N/A|
|Intellia Therapeutics||$43.10 million||104.19||-$99.53 million||($2.11)||-36.02|
StageZero Life Sciences has higher earnings, but lower revenue than Intellia Therapeutics.
This is a breakdown of current recommendations and price targets for StageZero Life Sciences and Intellia Therapeutics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|StageZero Life Sciences||0||0||0||0||N/A|
Intellia Therapeutics has a consensus price target of $49.04, indicating a potential downside of 35.48%. Given Intellia Therapeutics’ higher probable upside, analysts plainly believe Intellia Therapeutics is more favorable than StageZero Life Sciences.
Institutional & Insider Ownership
91.3% of Intellia Therapeutics shares are held by institutional investors. 5.1% of Intellia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This table compares StageZero Life Sciences and Intellia Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|StageZero Life Sciences||217.39%||N/A||-61.21%|
Intellia Therapeutics beats StageZero Life Sciences on 6 of the 11 factors compared between the two stocks.
StageZero Life Sciences Company Profile
StageZero Life Sciences Ltd. engages in the development and commercialization of proprietary molecular diagnostic tests for detection of diseases and for personalized health management, with a focus on cancer-related indications. Its products includes Sentinel Principle, and ColonSentry. The company was founded by Choong-Chin Liew and K. Wayne Marshall in 1998 and is headquartered in Markham, Canada.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company develops in vivo programs focusing on liver diseases, including transthyretin amyloidosis and hereditary angioedema, as well as other research programs comprising primary hyperoxaluria Type 1, alpha-1 antitrypsin deficiency, and Hemophilia B. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells; and acute myeloid leukemia. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; Ospedale San Raffaele; and GEMoaB Monoconals GmbH. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for StageZero Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for StageZero Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.